Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Infectious Disease
Rituximab
Questions discussed in this category
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
5 Answers available
Do you utilize post-vaccination IgG titers to detect common variable immunodeficiency in patients who are about to start or are actively on B cell depleting therapy?
2 Answers available
Is there a role for antibody testing to confirm vaccine response for patients on rituximab after COVID-19 vaccination?
1 Answer available
Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?
1 Answer available
24776
15774
10024
8621
Papers discussed in this category
Rheumatol Int, 2020 Sep 18
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
Hepatology (Baltimore, Md.), 2018 Apr
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
Gastroenterology, 2025 Feb
AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals.
Lancet Haematol, 2018 Oct
Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review.
Related Topics in Infectious Disease
Breast Cancer
Hematologic Malignancies
Radiation Oncology
Gynecologic Oncology
Gastrointestinal Cancers
Pediatric Hematology/Oncology
Sarcoma
Thoracic Malignancies
Bladder Cancer
Medical Oncology